Company news
Fulcrum Therapeutics, Inc. news in 2020
Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
December 8, 2020
Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
November 9, 2020
Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
November 3, 2020
Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8: 00 a.m. ET
November 2, 2020
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
October 4, 2020
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
September 30, 2020
Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting
September 24, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
August 10, 2020
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
August 10, 2020
Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8: 00 a.m. ET
August 4, 2020
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
July 20, 2020
Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients
June 23, 2020
Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19
June 9, 2020
Fulcrum Therapeutics Completes $68.5 Million Private Placement
June 9, 2020
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
May 20, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
May 12, 2020
Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
May 10, 2020
Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8: 00 a.m. ET
May 6, 2020
Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease
April 12, 2020
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
April 1, 2020
Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
March 23, 2020
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results
March 4, 2020
Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
February 27, 2020
Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
February 25, 2020
Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio
January 28, 2020
Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors
January 5, 2020